|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2003-09-15 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-05-21 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
A Phase I, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Subjects
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of L606 for Inhalation in Healthy Subjects
The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.
100 项与 国邑药品科技股份有限公司 相关的临床结果
0 项与 国邑药品科技股份有限公司 相关的专利(医药)
100 项与 国邑药品科技股份有限公司 相关的药物交易
100 项与 国邑药品科技股份有限公司 相关的转化医学